Abnormal brain metabolism as a biomarker for evaluating therapeutic approaches in Huntington’s disease

Author： Parievsky Anna   Cepeda Carlos   Levine Michael S  

Publisher： Future Medicine

ISSN： 1479-6708

Source： Future Neurology, Vol.7, Iss.5, 2012-09, pp. : 527-530

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Huntington’s disease: pathomechanism and therapeutic perspectives

By Gárdián G.   Vécsei L.  

Journal of Neural Transmission, Vol. 111, Iss. 10-11, 2004-10 ,pp. : 1485-1494

Springer Publishing Company

Access to resources Recommend Favorite

18F-fluorodeoxyglucose-PET as a biomarker in Huntington’s disease

By Ciarmiello Andrea   Squitieri Ferdinando  

Neurodegenerative Disease Management, Vol. 3, Iss. 6, 2013-12 ,pp. : 489-491

Future Medicine

Access to resources Recommend Favorite

Spotlight on Huntington’s Disease

By Strupp Michael  

Journal of Neurology, Vol. 251, Iss. 1, 2004-01 ,pp. : 120-121

Springer Publishing Company

Access to resources Recommend Favorite

HUNTINGTON’S DISEASE

By Barker Roger  

Brain, Vol. 127, Iss. 1, 2004-01 ,pp. : 233-234

Oxford University Press

Access to resources Recommend Favorite

Striatal neural grafting improves cortical metabolism in Huntington’s disease patients

By Gaura Véronique  

Brain, Vol. 127, Iss. 1, 2004-01 ,pp. : 65-72

Oxford University Press

Access to resources Recommend Favorite